Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tourmaline Bio

18.80
+1.7610.33%
Post-market: 17.86-0.9400-5.00%19:52 EDT
Volume:628.22K
Turnover:11.49M
Market Cap:482.08M
PE:-6.74
High:18.82
Open:17.72
Low:17.53
Close:17.04
Loading ...

Tourmaline Bio Initiated at Outperform by Wedbush

Dow Jones
·
06 Mar

Tourmaline Bio Inc : Wedbush Initiates Coverage With Outperform Rating; Price Target $42

THOMSON REUTERS
·
06 Mar

Wedbush Initiates Tourmaline Bio at Outperform With $42 Price Target

MT Newswires Live
·
06 Mar

Tourmaline Bio initiated with an Outperform at Wedbush

TIPRANKS
·
06 Mar

Tourmaline Bio to Present at the Leerink Partners Global Healthcare Conference 2025

GlobeNewswire
·
03 Mar

Tourmaline Bio Initiated at Outperform by LifeSci Capital

Dow Jones
·
25 Feb

Tourmaline Bio management to meet with Truist

TIPRANKS
·
20 Feb

Tourmaline Bio to Present at the Guggenheim Securities SMID Cap Biotech Conference

GlobeNewswire
·
27 Jan

Tourmaline Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr. Paul M. Ridker

GlobeNewswire
·
10 Jan

Tourmaline Bio: Promising Cardiovascular and Innovative Indications Drive Buy Rating Amid Upcoming Data Milestones

TIPRANKS
·
08 Jan

Truist Financial Sticks to Its Buy Rating for Tourmaline Bio (TRML)

TIPRANKS
·
11 Dec 2024

Tourmaline Bio Price Target Maintained With a $49.00/Share by HC Wainwright & Co.

Dow Jones
·
11 Dec 2024

Tourmaline Bio Updates on Clinical Progress and Outlook

TIPRANKS
·
11 Dec 2024

Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day

GlobeNewswire
·
10 Dec 2024

Tourmaline Bio to host investor day

TIPRANKS
·
09 Dec 2024

BMO Capital Initiates Tourmaline Bio at Outperform With $50 Price Target

MT Newswires Live
·
06 Dec 2024